Optimal Use of Capivasertib: Dosage, Administration, and Monitoring Guidelines

Introduction

LuciCapiva (Capivasertib) is a revolutionary oral medication designed to treat cancers driven by PIK3CA mutations, such as hormone receptor-positive, HER2-negative breast cancer and other solid tumors. By targeting the PI3K/AKT pathway, LuciCapiva offers a personalized approach to cancer treatment, improving outcomes for patients with specific genetic profiles.

Key Features

• Brand Name: LuciCapiva
• Generic Name: Capivasertib
• Formulation: Oral tablets
• Dosage Strengths: 160 mg and 200 mg

Indications

LuciCapiva is approved for:

1. Hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutations.
2. Other solid tumors confirmed to have PIK3CA mutations via molecular testing.

Dosage and Administration

• Initial Dose: 160 mg or 200 mg once daily, as prescribed by your oncologist.
• Duration: Continue until disease progression or unacceptable toxicity occurs.
• Administration:
• Take at the same time daily, with or without food (maintain consistency).
• Swallow the tablet whole with water; do not crush or chew.

Adjustments and Monitoring

1. Renal Impairment: Dose adjustments may be needed for moderate to severe kidney dysfunction.
2. Hepatic Impairment: Monitor liver enzymes regularly; adjust dose if necessary.
3. Blood Tests: Regular monitoring of liver function, blood counts, and electrolytes is essential.

Contraindications

• Hypersensitivity: Avoid if allergic to Capivasertib or any tablet components.
• Pregnancy/Breastfeeding: Not recommended due to potential harm to the fetus or infant.

Warnings and Precautions

1. Infections: Monitor for signs of infection (e.g., fever, chills); treat promptly.
2. Liver Toxicity: Discontinue if severe liver injury occurs (e.g., elevated ALT/AST).
3. QT Prolongation: Assess cardiac risk factors; monitor for arrhythmias.

Conclusion

LuciCapiva (Capivasertib) is a groundbreaking treatment for cancers with PIK3CA mutations, offering targeted therapy with the potential to improve survival and quality of life. As research continues, LuciCapiva may pave the way for further advancements in precision oncology, providing hope for patients with limited treatment options.